The outlook for T-cell malignancies remain poor due to the lack of effective therapeutic options. Chimeric antigen receptor (CAR) immunotherapy has recently shown promise in clinical trials for B-cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results